Small cap company (market value $538.4) in clinical stage that is developing therapies for people with immune mediated disease - targeting 7% of the population who suffer from such disease with an increasing incidence.
2 main therapies in development for ocular disease, other drugs for covid, ovarian cancer, psoriasis and atopic asthma. Strong upside potential for 2021 if trials show success